Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(72)
•••

Comment by flashcashon Feb 12, 2022 1:02am

214 Views

Post# 34422752

RE:RE:RE:RE:Going back to the $2.80 highs.....

GJS471 wrote:
I think news will be scarce until the Q4 results are ready to be released, and if the past two years are any indication, they probably will not be out until mid march.

We have some pipeline products around phase 3 so interesting times ahead.

GLA

<< Previous

Bullboard Posts

Next >>

Progressing Canada’s Great Atlantic Salt Project towards production